James Michael Mountz

Dr. James Michael Mountz

University of Pittsburgh, Pittsburgh, Pennsylvania, USA
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in Cancer Management and Research
Verified
Journal Article
Open access
James Michael MountzJames Michael Mountz
James Michael Mountz
RARafay Ahmed
Rafay Ahmed
MOMatthew J Oborski
Matthew J Oborski
FLFrank S Lieberman
Frank S Lieberman
MHMisun Hwang
Misun Hwang
Malignant gliomas consist of glioblastomas, anaplastic astrocytomas, anaplastic oligodendrogliomas and anaplastic oligoastrocytomas, and some less common tumors such as anaplastic ependymomas and anaplastic gangliogliomas. Malignant gliomas have high morbidity and mortality. Even with optimal treatment, median survival is only 12–15 months for glioblastomas and 2–5 years for anaplastic gliomas. However, recent advances in imaging and quantitative analysis of image data have led to earlier diagnosis of tumors and tumor response to therapy, providing oncologists with a greater time window for therapy management. In addition, improved understanding of tumor biology, genetics, and resistance mechanisms has enhanced surgical techniques, chemotherapy methods, and radiotherapy administration. After proper diagnosis and institution of appropriate therapy, there is now a vital need for quantitative methods that can sensitively detect malignant glioma response to therapy at early follow-up times, when changes in management of nonresponders can have its greatest effect. Currently, response is largely evaluated by measuring magnetic resonance contrast and size change, but this approach does not take into account the key biologic steps that precede tumor size reduction. Molecular imaging is ideally suited to measuring early response by quantifying cellular metabolism, proliferation, and apoptosis, activities altered early in treatment. We expect that successful integration of quantitative imaging biomarker assessment into the early phase of clinical trials could provide a novel approach for testing new therapies, and importantly, for facilitating patient management, sparing patients from weeks or months of toxicity and ineffective treatment. This review will present an overview of epidemiology, molecular pathogenesis and current advances in diagnoses, and management of malignant gliomas.

14 July 2011 in International Journal of Molecular Imaging
Verified
Journal Article
Open access
PDF file
SKSunhee Kim
Sunhee Kim
James Michael MountzJames Michael Mountz
James Michael Mountz
Epilepsy surgery is highly effective in treating refractory epilepsy, but requires accurate presurgical localization of the epileptogenic focus. Briefly, localization of the region of seizure onset traditionally dependents on seizure semiology, scalp EEG recordings and correlation with anatomical imaging modalities such as MRI. The introduction of noninvasive functional neuroimaging methods, including single-photon emission computed tomography (SPECT) and positron emission tomography (PET) has dramatically changed the method for presurgical epilepsy evaluation. These imaging modalities have become powerful tools for the investigation of brain function and are an essential part of the evaluation of epileptic patients. Of these methods, SPECT has the practical capacity to image blood flow functional changes that occur during seizures in the routine clinical setting. In this review we present the basic principles of epilepsy SPECT and PET imaging. We discuss the properties of the SPECT tracers to be used for this purpose and imaging acquisition protocols as well as the diagnostic performance of SPECT in addition to SPECT image analysis methods. This is followed by a discussion and comparison to F-18 FDG PET acquisition and imaging analysis methods.

1 January 2015 in NeuroImage: Clinical
Verified
Journal Article
Open access
James Michael MountzJames Michael Mountz
James Michael Mountz
CLCharles M. Laymon
Charles M. Laymon
ACAnn D. Cohen
Ann D. Cohen
ZZZheng Zhang
Zheng Zhang
JPJulie C. Price
Julie C. Price
CMChester A. Mathis
Chester A. Mathis
Neuritic amyloid plaques and neurofibrillary tangles, the hallmark pathologic lesions of Alzheimer's disease, are thought to develop before the symptoms of brain failure are clinically detectable. Imaging methods capable of detecting the presence of neuritic amyloid plaques should improve a clinician's ability to identify Alzheimer's disease during the earliest symptomatic phase and to identify at-risk individuals presymptomatically. Currently the best studied amyloid imaging ligand is [(11)C]Pittsburgh Compound B ([(11)C]PiB). However, the 20-minute half-life of this radiotracer limits its use. This study is designed to evaluate the performance characteristics of [(18)F]flutemetamol and to independently compare results to [(11)C]PiB in the same subjects. Twenty-three subjects, 15 cognitively normal (NL) and 8 with a clinical diagnosis of Alzheimer's Dementia (AD), underwent [(11)C]PiB and [(18)F]flutemetamol PET scans within 28 days of study enrollment. We studied both normal and AD subjects to assess the uptake characteristics across a range of amyloid positivity. Blinded visual reads were conducted by five raters. Correlation analyses were performed between cortical SUVR for the two tracers and also between rater scores and SUVR for each tracer. Overall reader accuracy for classifying scans as amyloid positive or negative was determined for each tracer using SUVR classification as the standard. The linear correlation coefficient between global cortical SUVR for the two tracers was R(2) = 0.85, indicating that both tracers have similar retention characteristics. The two tracers were well correlated for rater-determined AD-like positivity (Cohen κ = 0.82). Averaged visual ratings and global cortical SUVR disagreed on their classification in 2/23 [(11)C]PiB scans and 4/23 [(18)F]flutemetamol scans. [(11)C]PiB and [(18)F]flutemetamol have similar retention characteristics across a range of amyloid negative to positive subjects. Both tracers performed similarly when a standardized visual read technique was used to classify scans as amyloid-positive or amyloid-negative and correlated well with SUVR classifications. However, care in visual interpretation of amyloid positive versus amyloid negative regions should be taken, particularly in the case of [(18)F]flutemetamol when considering cortical vs. white-matter retention.

12 February 2014 in Brain and Behavior
Verified
Journal Article
Open access
PDF file
MOMatthew J. Oborski
Matthew J. Oborski
CLCharles M. Laymon
Charles M. Laymon
FLFrank S. Lieberman
Frank S. Lieberman
JDJan Drappatz
Jan Drappatz
RHRonald L. Hamilton
Ronald L. Hamilton
James Michael MountzJames Michael Mountz
James Michael Mountz
Objectives: The authors present the first use of the novel positron emission tomography (PET) apoptosis tracer 18F‐labeled 2‐(5‐fluoro‐pentyl)‐2‐methyl‐malonic acid (18F‐ML‐10) for early‐therapy response assessment of a newly diagnosed glioblastoma multiforme (GBM) patient.Case report: A 71‐year‐old male with a newly diagnosed GBM received 18F‐ML‐10 PET scans prior to therapy initiation (baseline) and after completing 3 weeks of whole‐brain radiation therapy with concomitant temozolomide chemotherapy (early‐therapy assessment, ETA). The baseline 18F‐ML‐10 PET scan showed increased tracer uptake at the site of the GBM, with highest activity toward the central portion of the tumor. At the ETA time point, a new distribution of tracer uptake was observed compared to baseline. Normalized pixel‐by‐pixel subtraction of baseline from ETA was used to quantify change in tracer distribution between 18F‐ML‐10 PET imaging time points. Results of this analysis showed reduction in 18F‐ML‐10 uptake at the site of greatest baseline uptake, but increased uptake around the periphery of the tumor at the early‐therapy time point.Conclusion: The changing patterns of 18F‐ML‐10 uptake between baseline and ETA are suggestive for therapy‐induced tumor cellular apoptosis.

22 February 2018 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
NNNghi C. Nguyen
Nghi C. Nguyen
MYMelissa K. Yee
Melissa K. Yee
ATAbuzar M. Tuchayi
Abuzar M. Tuchayi
JKJohn M. Kirkwood
John M. Kirkwood
HTHussein Tawbi
Hussein Tawbi
James Michael MountzJames Michael Mountz
James Michael Mountz
Introduction: This pilot study aimed at exploring the utility of the proliferation tracer F-18 fluorothymidine (FLT) and positron-emission tomography (PET)/magnetic resonance imaging (MRI) (FLT–PET/MRI) for early treatment monitoring in patients with melanoma brain metastasis (MBM) who undergo targeted therapy or immunotherapy. Material and Methods: Patients with newly diagnosed MBM underwent baseline and follow-up FLT–PET/MRI scans at 3–4 weeks of targeted therapy or immunotherapy. Up to six measurable brain lesions ≥1.0 cm per subject, as identified on T1-weighted post-gadolinium images, were included for quantitative analyses. The maximum SUV of each lesion was divided by the mean SUV of the pons to obtain the SUV ratio (SUVR). Results: Five enrolled subjects underwent the baseline FLT–PET/MRI study in which the MBM showed a median size of 1.7 cm (range 1.0–2.9) and increased metabolic activity with SUVR of 9.9 (range 3.2–18.4). However, only two subjects (cases #1 and #2) returned for a follow-up scan. At baseline, a total of 22 lesions were analyzed in all five subjects, which showed a median size of 1.7 cm (range 1.0–2.9) and median SUVR of 9.9 (range 3.2–18.4). At follow-up, case #1 was a 55-year-old man who received targeted BRAF inhibitor and MEK inhibitor therapy with dabrafenib and trametinib. Fused PET/MRI data of six measured lesions demonstrated a significant reduction in MBM proliferative activity (median −68%; range −38 to −77%) and size (median −23%; range −4 to −55%) at three weeks of therapy. Nevertheless, the subject eventually progressed and died 13 months after therapy initiation. Case #2 was a 36-year-old man who received immunotherapy with nivolumab and ipilimumab. The five measured MBM lesions showed a mixed response at both proliferative and morphologic imaging at 1-month follow-up. Some lesions demonstrated interval decrease while others interval increase in proliferative activity with a median −44% (range −77 to +68%). On MRI, the size change was +7% (range −64 to +50%). The therapy was switched to dabrafenib and trametinib, which led to a partial response. The patient is still alive 16 months following therapy initiation. Conclusion: The five cases presented show the potential benefit of hybrid FLT–PET/MRI for the diagnosis of MBM and treatment monitoring of targeted therapy and immunotherapy. However, further studies are required to assess their complementary role in distinguishing true progression from pseudoprogression.

21 July 2012 in Magnetic Resonance Imaging
Verified
Journal Article
Closed access
CLCharles M. Laymon
Charles M. Laymon
MOMatthew J. Oborski
Matthew J. Oborski
VLVincent K. Lee
Vincent K. Lee
DDDenise K. Davis
Denise K. Davis
EWErik C. Wiener
Erik C. Wiener
James Michael MountzJames Michael Mountz
James Michael Mountz